Key Technologies
- Lead Drug Candidate - PEHRG214 represents a new biological approach to the treatment of HIV infected patients who have progressed to AIDS
- Potent Immune Modulator –- a microparticle immune stimulator ("MIS416") with multiple pathogen-associated molecular pattern recognition receptors (TLR & NOD ligands) that act in a safe, well defined and synergistic manner.
In addition to the technologies listed above Virionyx has a cGMP licensed manufacturing facility and process for both programmes. Preclinical acute 7 day toxicology on the microparticle programme has been completed and MIS416 is free of any relevant toxicity issues/concerns.
